Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032080 · ClinicalTrials.gov registry record · Phase 2
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04032080: Completed Phase 2 study, sponsored by Baylor Research Institute.
NCT04032080 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04032080, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
Primary Outcome
To assess the objective response rate associated with LY3023414 and prexasertib in metastatic TNBC patients. Objective response is measured as prolonged clinical benefit; clinical benefit is defined as progression free survival on study therapy for at least 6 months.
Interventions
- COMBINATION_PRODUCT Drug 1: LY3023414; Drug 2: Prexasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2022-11-26 |
| Phase | Phase 2 |
What the finished NCT04032080 record still lists
NCT04032080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Drug 1: LY3023414; Drug 2: Prexasertib is the first listed.
NCT04032080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04032080 about?
NCT04032080 is a clinical study titled "LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer". This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
What is the current status of trial NCT04032080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-09-05. Estimated completion is 2022-11-26.
What interventions are being tested in trial NCT04032080?
The interventions under investigation include: Drug 1: LY3023414; Drug 2: Prexasertib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04032080?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04032080's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI